Predict risk of dose-related toxicity and responsiveness to 5-FU therapy.

Do not use to screen for celiac disease.  May be used to estimate severity of intestinal villous atrophy in confirmed celiac disease.

May be helpful in evaluating for autoimmune liver disease. For a more comprehensive reflex panel, refer to 2007210.

Evaluate for possible factor II deficiency.

Order to diagnose factor IX deficiency, detect factor IX inhibitors, and monitor factor IX replacement therapy.

Order to diagnose factor IX deficiency (hemophilia B) and monitor factor IX replacement therapy.

Order to detect factor V Leiden mutation.

Evaluate possible factor V deficiency.

Order to determine thrombotic risk in individuals known to be factor V Leiden heterozygotes.

Evaluate possible factor VII deficiency.

Order to diagnose factor VIII deficiency, detect factor VIII inhibitors, and monitor factor VIII replacement therapy.

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

Order to diagnose hemophilia A, acquired factor VIII deficiency, or as part of a diagnostic workup for von Willebrand disease. Not recommended when screening for thrombophilia.

Evaluate possible factor X deficiency.

Order to diagnose factor XI deficiency (hemophilia C).

Evaluate the cause of an isolated prolonged PTT in a patient who is not currently bleeding.

Assess genetic risk for thrombosis.

First-line test to diagnose FXIII deficiency. Appropriate for evaluation of patients with a bleeding disorder present with normal PT, PTT, and platelet count test results. Use for monitoring FXIII therapy and for confirming abnormalities detected on FXIII qualitative assay.

Most useful for acquired or severe FXIII deficiency testing. Abnormal results should be confirmed with quantitative testing (Factor XIII Activity 2006182)

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

Second-tier diagnostic or predictive test for familial adenomatous polyposis. Order if no variants were detected by APC sequencing, or concurrently with Familial Adenomatous Polyposis (APC) Sequencing (2004863), or if there is a known familial APC deletion.

Acceptable diagnostic or predictive test for familial adenomatous polyposis. For classic FAP, consider concurrent APC deletion/duplication analysis (2004920).

Preferred diagnostic or predictive test for familial adenomatous polyposis and MUTYH-associated polyposis.

Preferred test for suspected Familial Mediterranean Fever.

Consultation with a genetics counselor is advised. Useful when a pathogenic familial variant identifiable by sequencing is known.

Consultation with a genetics counselor is advised. Order for fetal testing to detect a previously characterized mutation in a family member.

Diagnostic testing for Fanconi anemia, group C.  Carrier screening for Fanconi anemia, group C.

Identification of patients with essential fatty acid deficiency, evaluation of nutritional status, and diet monitoring.

Confirm presence of disease; not recommended for initial testing.

Optimize drug therapy and monitor patient adherence.

Useful for general screening in contexts of compliance and/or abuse. A screen with reflex testing is the preferred method for ruling out amphetamine exposure. For follow-up testing of a presumptive result, Fentanyl and Metabolite, Urine Quantitative (0092570) is preferred.

Monitor patient adherence.

Preferred test to follow-up presumptive results. For general screening, Fentanyl, Urine Screen with Reflex to Quantitation (2012284) is preferred.

Aids in the diagnosis of iron deficiency anemia and iron overload. Monitor treatment of hemochromatosis.

Detect and quantify the extent of fetomaternal hemorrhage in pregnant or postpartum women. Assess the need for Rh immunoglobulin (eg, RhoGAM) for fetomaternal hemorrhage.

Diagnostic testing for FG syndrome.  Carrier screening for FG syndrome.

Recommended for the diagnosis of systemic sclerosis in patients negative for centromere, Scl-70, or RNA polymerase III antibodies. May predict skeletal muscle involvement and pulmonary arterial hypertension.

For evaluating coagulopathies (eg, disseminated intravascular coagulation), D-Dimer (0030057) is the preferred test. If FDP testing is being considered, this plasma test, rather than the serum test, is the recommended test.

Determine if fibrinogen deficiency is a potential cause of bleeding.

A follow-up test for decreased fibrinogen activity to determine if the decrease is due to insufficient fibrinogen or dysfunctional fibrinogen.

Assist in diagnosing dysfibrinogenemia.

Confirm diagnosis of ichthyosis vulgaris and differentiate vulgaris from other forms of ichthyosis.

Aid in the detection of antibodies to filaria. Consider blood smear with Giemsa staining test (0049025).

Optimize drug therapy and monitor patient adherence.

First-line test for prognostication of CN-AML.

First-line test for prognostication of CN-AML. This test also provides a FTL3 mutant allelic ratio.

Optimize drug therapy and monitor patient adherence.

Screening culture for fluoroquinolone-resistant organisms. Consider prior to trans-rectal prostate biopsy.

Optimize drug therapy and monitor patient adherence.

Optimize drug therapy and monitor patient adherence.

Aids in detection of folate deficiency.

Aids in detection of folate deficiency.

Use in conjunction with histologic and clinical information for the diagnosis of alveolar rhabdomyosarcoma.

Preferred test to diagnose fragile X syndrome in individuals with characteristic clinical symptoms or screen healthy individuals for carrier status with or without a positive family history.

Prenatal test for fetuses of mothers with fragile X premutations or full mutations.

Preferred test for detecting antibodies during acute or convalescent phase. Convalescent sera may be required for diagnosis.

Detects antibodies during convalescent phase. Convalescent sera may be required for diagnosis.

Detects antibodies during acute phase; paired concurrent specimen with IgG reduces false positive rate. Convalescent sera may be required for diagnosis.

Direct measure of free estradiol in serum. Most accurate measure of bioactive estradiol.

Diagnostic testing for Freeman-Sheldon syndrome.

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

May aid in monitoring glucose control for diabetes in specific disorders. Not recommended as a substitute for hemoglobin A1c except in specific populations.

Useful when screening for obstruction or absence of the seminal vesicles in males with azoospermia.

Not recommended. For suspicion of coccidioidal meningitis, refer to Coccidioides antibodies panel for CSF (0050710).

Not recommended. Refer to individual fungus-related tests appropriate to patient exposure.

Not recommended. Refer to individual fungus-related tests appropriate to patient exposure.